We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01026558
First Posted: December 4, 2009
Last Update Posted: August 28, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by (Responsible Party):
Basilea Pharmaceutica
  Purpose
The primary objective of this study is to compare the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of ceftobiprole in morbidly obese patients and non-obese patients. The secondary objectives are to assess the pharmacodynamics (the study of the action or effects a drug has on the body) and to assess safety and tolerability of ceftobiprole in order to support dosing recommendations in the morbidly obese population.

Condition Intervention Phase
Obesity Staphylococcal Skin Infections Streptococcal Infections Drug: Ceftobiprole Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Open-Label, Single Dose, Parallel Group Pharmacokinetic Study of Ceftobiprole in Morbidly Obese and Non-Obese Patients

Further study details as provided by Basilea Pharmaceutica:

Primary Outcome Measures:
  • The pharmacokinetics of ceftobiprole in morbidly obese patients and non-obese patients [ Time Frame: up to 30 days (up to 21 days screening plus 2 days open-label treatment phase plus 1-week follow-up). ]

Secondary Outcome Measures:
  • To assess the pharmacodynamics of ceftobiprole in morbidly obese patients and non-obese patients. [ Time Frame: Up to 30 days (up to 21 days screening plus 2 days open label treatment phase plus 1-week follow-up) ]
  • To assess safety and tolerability of ceftobiprole in order to support dosing recommendations in the morbidly obese population. [ Time Frame: Throughout the study from Day -1 through the post-study follow up ]

Enrollment: 25
Study Start Date: August 2007
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ceftobiprole (not morbidly obese subjects)
Ceftobiprole 500 mg single-dose over 2 hours.
Drug: Ceftobiprole
Ceftobiprole, 500 mg as single iv infusion over 2 hours
Experimental: Ceftobiprole (morbidly obese subjects)
Ceftobiprole 500 mg single-dose over 2 hours.
Drug: Ceftobiprole
Ceftobiprole, 500 mg as single iv infusion over 2 hours

Detailed Description:
This is an open-label (all people involved know the identity of the intervention), parallel-group, Phase 1 study in morbidly obese and non-obese men and women. A total of 25 patients (12 morbidly obese and 13 non-obese) patients will be enrolled in the study. Morbidly obese and nonobese patients are matched individually 1:1 by age (±10 years), sex, and renal function (as defined by creatinine levels in the urine). There are 4 phases in the clinical study: the pretreatment (screening/baseline) phase of up to 21 days; the 2-day open-label treatment phase when each patients receives a single 2-hour intravenous (directly into the vein) infusion of ceftobiprole 500 mg followed by multiple (up to 15) blood and urine samples drawn over the 24 hours following study drug administration; and the follow-up phase of approximately 1 week after the last blood sample when each patient will be monitored by telephone for development of new adverse events and assessment of ongoing adverse events. Each patient receives a single 2-hour infusion (directly into the vein) of ceftobiprole 500 mg
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Body mass index (BMI) =or > 40 kg/m2 or normal BMI between 18-30
  • Blood pressure 90-140 mm
  • Non-smoker

Exclusion Criteria:

  • History of medically significant illness
  • Uncontrolled hypertension
  • Uncontrolled high blood cholesterol and triglycerides
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01026558


Sponsors and Collaborators
Basilea Pharmaceutica
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Investigators
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  More Information

Additional Information:
Responsible Party: Basilea Pharmaceutica
ClinicalTrials.gov Identifier: NCT01026558     History of Changes
Other Study ID Numbers: CR014185
CSI-1008 ( Other Identifier: Basilea (Internal Reference) )
First Submitted: December 3, 2009
First Posted: December 4, 2009
Last Update Posted: August 28, 2012
Last Verified: August 2012

Keywords provided by Basilea Pharmaceutica:
Obesity, Ceftobiprole
Skin Infections
Staphylococcal Skin Infections
Bacterial Skin Infections
Streptococcal Infection

Additional relevant MeSH terms:
Infection
Communicable Diseases
Skin Diseases, Infectious
Streptococcal Infections
Staphylococcal Skin Infections
Skin Diseases
Gram-Positive Bacterial Infections
Bacterial Infections
Staphylococcal Infections
Skin Diseases, Bacterial
Ceftobiprole
Ceftobiprole medocaril
Cephalosporins
Anti-Bacterial Agents
Anti-Infective Agents